About

Elizabeth Jungman

Elizabeth Jungman

  • Director
  • Public Health,
  • The Pew Charitable Trusts

Profile

Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation and the safety of prescription drugs, over-the-counter medicines, and other consumer health care products.

Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.

Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.

Recent Work

View All
  • What Are Compounded Drugs, and How Can They Be Kept Safe?

    Pharmaceutical compounding is the creation of medications for patients whose clinical needs cannot be met by commercially available products approved by the Food and Drug Administration. For example, if a patient who cannot swallow pills needs a liquid version of a medicine that is FDA-approved only in pill form, a compounding pharmacy can make the medication. Read More

  • A Q&A With a Survivor of Contaminated Compounded Drugs

    In 2012 and 2013, patients across the country were injected with fungus-contaminated drugs that had been made and distributed by a Massachusetts compounding pharmacy. More than 60 people died of fungal meningitis, and more than 750 people in 20 states became seriously ill. Many of these patients still struggle with chronic, even disabling, health problems, including pain and mobility challenges... Read More

  • Full Implementation and Enforcement of Drug Compounding Law Will Save Lives

    Four years ago today, Congress responded to a catastrophic fungal meningitis outbreak by enacting the bipartisan Drug Quality and Security Act (DQSA). That outbreak—the most extensive known example of harm to patients caused by compounded drugs—sickened at least 750 people, killing more than 60. Compounded drugs are specialized medications for patients whose clinical needs cannot be... Read More

Media Contact

Laurie Boeder

Director, Communications